-
Quince Therapeutics NasdaqGS:QNCX Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Location: 611 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.quincetx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
31.44M
Cash
31.6M
Avg Qtr Burn
-8.288M
Short % of Float
1.65%
Insider Ownership
12.71%
Institutional Own.
22.26%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
EryDex Details Rare genetic disease, Neurological disorder, Ataxia Telangiectasia | Phase 3 Data readout | |
Atuzaginstat (COR388) / Lysine gingipain inhibitor Details Alzheimer's disease, Neurological disorder | Failed Discontinued | |
COR588 (Lysine gingipain inhibitor) Details Mental health, Alzheimer's disease, Neurological disorder | Failed Discontinued | |
Atuzaginstat (COR388) / Lysine gingipain inhibitor Details Parkinson's disease | Failed Discontinued | |
Atuzaginstat (COR388) (Lysine gingipain inhibitor) Details Periodontal disease | Failed Discontinued |